you get your prescription from a GP, pharmacy, or another provider, and use WeightWatchers programme for behavioural support alongside your treatment
The American Diabetes Association (ADA) guidelines updated in 2023 recommend GLP-1 receptor agonists as a preferred treatment option for many patients with type 2 diabetes, particularly those with or at high risk for cardiovascular disease or kidney disease
Hewagalamulage SD, Lee TK, Clarke IJ, et al
Weight changes during peptide therapy are more likely related to other factors
Understanding eligibility, safety considerations, and NHS access pathways is essential for menopausal women considering this therapeutic approach alongside lifestyle modifications recommended by NICE and the NHS
Semaglutide candidates will have a BMI (body mass index) of at least 30